Mid-Life Plasmalogens and Other Metabolites with Anti-Inflammatory Properties are Inversely Associated with Long term Cardiovascular Disease Events: Heart SCORE Study

Abstract

BackgroundPreclinical data have shown that low levels of plasmalogens and other metabolites with anti-inflammatory properties may impact metabolic disease processes. However, the association between mid-life levels of such metabolites and late-life atherosclerotic cardiovascular disease (ASCVD) is not known.MethodsWe characterized the midlife plasma metabolomic profile (1,228 metabolites) of 1,852 participants (age 58.1±7.5 years, 69.6% female, 43.6% self-identified as Black) enrolled in the Heart Strategies Concentrating on Risk Evaluation (Heart SCORE) study. Participants were followed for ∼16 years for incident ASCVD events (nonfatal MI, acute ischemic syndrome, coronary revascularization and ASCVD mortality). We used regression model to assess associations of metabolites with ASCVD events. We assessed the impact of genetic variants using whole-exome sequencing with single-variant analysis for common variants and gene-based burden tests for rare variants. We used unbiased and candidate gene approaches to explore genetic associations with metabolites found to be associated with ASCVD events.ResultsA total of twelve metabolites were independently associated with incident ASCVD in fully adjusted models over a median of 12.1 years. A subset of plasmalogens showed an independent inverse association with incident ASCVD events [1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (OR, 0.54; 95% CI, 0.40-0.74); 1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (OR, 0.57; 95% CI, 0.42-0.78), 1-methylnicotinamide1-(1-enyl-stearoyl)-2-arachidonoyl-GPE (OR, 0.76; 95% CI, 0.65-0.89)]. Metabolome-wide genetic analysis revealed that two of these plasmalogen metabolites were strongly influenced by polymorphisms of the rs174535, an eQTL for FADS1 and FADS2 genotype. Two amino acid metabolites (2-oxoarginine [OR, 0.42; 95% CI, 0.25-0.69], alpha-ketobutyrate [OR, 0.62; 95% CI, 0.49-0.80]) and a bilirubin degradation product (C16H18N2O5[OR, 0.50; 95% CI, 0.38-0.66) were inversely associated with ASCVD events.ConclusionsHigher mid-life levels of three plasmalogens, two amino acid metabolites, and a bilirubin degradation product, all of which have anti-inflammatory properties, are associated with lower risk of late-life ASCVD events. Further research is needed to determine whether these metabolites play a causal role in ASCVD and may be a target for future therapies.